Programme Thesis
ATMAN 3.0 is an eight-week accelerator by TIH IIT Bombay, funded by India's DST, that funds and mentors early-stage HealthTech startups to become investment-ready, culminating in a Demo Day where startups pitch to investors. It exists to bridge the gap between research and commercialization in healthcare, supporting ventures that address critical health challenges with technology.
Selection Criteria
Eligibility: Early-stage HealthTech ventures (likely pre-seed/seed, with a prototype or proof-of-concept).
- Focus on HealthTech: medical devices, digital health, assistive care, clinical monitoring, diagnostics, therapeutics.
- Innovation and research-based solutions (translational research).
- Potential for investment-readiness and scalability.
- Competitive selection: 13 startups chosen from 173 pitches (approx. 7.5% acceptance rate).
- Commitment to 8-week program and Demo Day participation.
- Likely criteria: team capability, clinical relevance, market potential, regulatory readiness, and alignment with India's healthcare needs (though international startups may be considered).
Past Winners / Cohort Profiles
The current cohort (ATMAN 3.0) includes 13 startups, e.g., Prezitec Health (needle tracking), Shitashii Innovations (speech device), ATTOX Research (AMR testing), Queliz Lifetech (rehab robot), Brela Innovations (breast health), Intecog Logistech (pharma logistics), Raycura Medical (stroke rehab), Saintiant Technologies (vital monitoring), DeepFacts (AI wearable), MicroHeal (digital therapeutic for gut), Miraii.ai (smart ring for seniors), Mythri MedTech (cardio-metabolic vitals), Kode Blue (emergency care). Archetype: early-stage, hardware or AI-driven, addressing specific clinical or health access problems, with a prototype and clear patient impact.
Ideal Candidate Fingerprint
The ideal applicant is an early-stage HealthTech startup with a validated prototype or proof-of-concept, addressing a critical healthcare challenge (e.g., diagnostics, monitoring, rehabilitation, AMR) with a strong research foundation. They should have a clear path to commercialization, a committed team, and be ready to engage in intensive mentorship and investor pitching.
Recommended Framing
For Eniola Olutogun, the strongest angle is to position the venture as an AI-driven drug discovery platform that addresses antimicrobial resistance (AMR) and oncology drug resistance, directly aligning with ATMAN's focus on critical health challenges (as seen in ATTOX's AMR solution). The venture's ability to predict drug resistance mutations from protein sequence alone (no structure required) is a unique, research-backed innovation that can accelerate drug development and improve patient outcomes, fitting the accelerator's emphasis on translational research and investment-readiness. Highlight the proof-of-concept (AUROC 0.804 on Platinum) and the potential to partner with pharma (e.g., Servier) to demonstrate commercial traction.
Watch Out
Potential eligibility concerns: ATMAN is based in India and may prioritize Indian startups or those addressing India's healthcare needs; international startups may be considered but could face visa/logistics challenges. The program is 8 weeks in-person (Demo Day in Mumbai), requiring travel and commitment. The venture is not yet incorporated, which may be a hurdle for funding disbursement. Also, the program's focus is broad HealthTech, but the venture is computational biology/pharma AI, which may be seen as less 'hardware' or 'clinical' compared to typical winners.
Research History
2026-08-04 20:09 · medium confidence
2026-07-31 16:57 · medium confidence